Retatrutide

Mechanism

Activates GLP-1, GIP, and glucagon pathways affecting satiety, insulin, and lipolysis.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Aggressive fat loss
• Energy expenditure
• Satiety control

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

approximately 6 days (human, SC) — study. Urva et al., Lancet 2022; phase 1b multiple ascending dose of LY3437943.

Storage

not on file — no stability record on file — investigational, no label; only research-chem retailer claims found.

In sport (WADA 2026)

Prohibited, at all times — S0 catch-all. the list Not named. In clinical development with no regulatory approval, which is exactly the S0 wording ('drugs under pre-clinical or clinical development').

The half-life on file is 6 d, measured subcutaneously. On the schedule this record states — weekly — each dose is still at 45% of its own peak when the next is given, so the doses overlap: the peaks build to 1.80× the first.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Nausea

  Very common in trialsonset: Dose escalationreported reversible

• Increased heart rate

  Dose-dependent in trialsonset: Ongoingreported reversible

Literature on file 3

• human observational
  NCT04881760: A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities graded on: a registered clinical study — “clinicaltrials.gov”
• human RCT
  Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (New England Journal of Medicine 2023, cited 1022x) graded on: a phase 2 trial — “Phase 2 Trial”
• human RCT
  Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (The Lancet 2023, cited 380x) graded on: randomised and double-blind — “randomised, double-blind”

What is circulated not evidence 5

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose common nothing on file either way

  Community guides recommend starting well below the 2 mg clinical protocol, commonly at 0.5-1 mg weekly, on the reasoning that a lower dose may already work.

  why go to full dose if half dose seems to be working fine for you?

  On the record Dosing on file is 0.25-12 mg weekly (trial range, unverified flag set); no record supports any specific community starting dose below 2 mg.

  Source 1

• unverified community data titration common nothing on file either way

  Slower titration than the trial schedule is widely advised — escalating every 6-8 weeks rather than every 4, and settling at 4-8 mg rather than pushing to 12 mg.

  The 'suggested' schedule for increasing seems to be too fast

  On the record The record holds the trial dose range only; no titration schedule of any kind is on file, community or clinical.

  Source 1

• unverified community data side effect common nothing on file either way

  A 'sunburn' or tingling skin sensation (dysesthesia) is widely reported by community users as a retatrutide-specific side effect.

  the weird skin thing

  On the record Side effects on file are nausea (very common in trials) and increased heart rate (dose-dependent in trials); no skin dysesthesia record exists.

  Source 1

• unverified community data side effect common agrees with the record

  Elevated resting heart rate of 5-15 bpm is commonly reported by community users.

  Elevated resting heart rate: 5–15 bpm

  On the record Increased heart rate is on file as dose-dependent in trials; the specific 5-15 bpm figure is not on file.

  Source 1

• unverified community data sourcing occasional nothing on file either way

  Community posts report that compounded or grey-market retatrutide varies in potency batch to batch, with appetite suppression changing after a supplier switch.

  If I eat anything I am hungry again within an hour

  On the record Nothing on file; the storage record notes only research-chem retailer claims exist for stability, and no potency-variance record exists.

  Source 1

Identity

Classified as

Lipolysis Stimulationmechanism

This mechanism is the source of the most common category error on the site. A record can be well supported for lipolysis and carry nothing at all for fat loss, and the two live in different fields with different rungs on the ladder at /evidence/rubric.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• Retatrutide
• glp3 r
• glp 3 r
• glp 3 rt
• glp 3 reta
• glp 3 “r”
• glp 3 r box of 10
• glp 3r – /kit
• reta glp 3
• reta 3
• glp 3
• glp3
• glp3r
• glp3rt
• glp 3r
• glp 3rt
• glp 3 rta
• aminoglp 3 rt
• reta

Listed prices 454

What 121 shops we track listed for Retatrutide, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.